CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
开创癌症免疫治疗的未来：计算建模驱动的合成免疫学新时代
英文原题：Pioneering the Future of Cancer Immunotherapy: A New Era of Synthetic Immunology through Computational Modeling.
查看英文原题
Pioneering the Future of Cancer Immunotherapy: A New Era of Synthetic Immunology through Computational Modeling.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞免疫疗法改变了血液系统恶性肿瘤治疗，但其在实体瘤中的应用受限于特异性不足和对健康组织的潜在毒性。为解决这些局限，研究者开发了一种整合方法，将高通量机器人平台与数学建模结合，系统评估并优化 T 细胞功能。该新方法揭示了 CAR-T 细胞内此前未知的信号串扰，并据此开发出优化的 CAR 设计。改进后的 CAR-T 平台显著增强抗肿瘤活性，同时最大限度减少对健康组织的毒性。这些发现突显计算建模在模拟免疫细胞行为方面的作用，并为设计更精准、有效的癌症免疫疗法提供稳健框架。（发表于 2015th Meeting，2024 年 12 月 6 日。）
展开英文摘要原文
Chimeric Antigen Receptor (CAR) T-cell immunotherapy has revolutionized the treatment of hematological malignancies.
However, its application to solid tumors has been hindered by poor specificity and potential toxicity to healthy tissues. To address these limitations, we developed an integrated approach combining a high-throughput robotic platform with mathematical modeling to systematically evaluate and optimize T-cell function. This novel approach enabled us to uncover previously unknown signaling crosstalk within CAR T-cells, leading to the development of an optimized CAR design.
Our enhanced CAR T-cell platform demonstrates significantly improved anti-tumor activity while minimizing toxicity to healthy tissues.
These findings highlight the power of computational modeling in simulating immune cell behaviors and provide a robust framework for designing more precise and effective cancer immunotherapies. (Presented at the 2015th Meeting, December 6th, 2024).
论文信息
- 作者
- Kondo T
- 单位
- Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health.
- 期刊
- The Keio journal of medicine2025
- 原文标识
- PubMed 40128934 · DOI 10.2302/kjm.ABSTRACT_74-1